rhTPO联合紫杉醇与卡铂化疗治疗晚期卵巢癌的效果及优势分析

Effect and advantage of rhTPO combined with paclitaxel and carboplatin in the treatment of advanced ovarian cancer

目的分析重组人血小板生成素(rhTPO)联合紫杉醇与卡铂化疗治疗晚期卵巢癌的效果及优势。方法选取2019年2月至2021年12月陕西省汉中市三二〇一医院收治的105例晚期卵巢癌患者为对象,采用简单随机法分为两组。对照组给予紫杉醇联合卡铂化疗方案,同时给予重组人白细胞介素-11(rhIL-11)治疗,观察组在化疗方案基础上给予rh TPO治疗。比较两组疾病控制率、促血小板增值效果及副反应情况,检测两组血小板计数(PLT)最低值、肿瘤标志物的差异。结果观察组疾病控制率90.57%(48/53)与对照组的86.54%(45/52)比较,差异无统计学意义(P>0.05)。治疗后两组PLT最低值均较治疗前升高,肿瘤标志物均较治疗前下降,且观察组治疗后PLT最低值高于对照组,治疗后肿瘤标志物与对照组比较,差异无统计学意义(P>0.05)。观察组血小板恢复至75×10^(9)/L以上需(3.78±1.12)d,恢复至100×10^(9)/L以上需(5.74±1.32)d,均明显短于对照组的(5.23±1.25)d和(8.97±1.46)d,差异有统计学意义(P<0.05)。两组血小板减少、血红蛋白降低、中性粒细胞减少、白细胞降低、胃肠道反应、肝功能损害、周围神经异常、脱发、发热等副反应发生率比较,差异均无统计学意义(P>0.05)。结论rhTPO联合紫杉醇与卡铂化疗治疗晚期卵巢癌可增加血小板数量,并不会增加副反应,值得临床应用。

Objective To analyze the efficacy and advantages of recombinant human thrombopoietin(rhTPO)combined with paclitaxel and carboplatin in the treatment of advanced ovarian cancer.Methods 105 patients with advanced ovarian cancer who were admitted to the Hanzhong City No.3201 Hospital from February 2019 to December 2021 were selected as the subjects,and divided into two groups by simple random method.The control group was treated with paclitaxel combined with carboplatin chemotherapy and rhIL-11,while the observation group was treated with rhTPO on the basis of chemotherapy.The control rate of the disease,the effect of promoting platelet proliferation and the side effects of the two groups were compared,and the difference of the lowest value of platelet count(PLT)and tumor markers of the two groups were detected.Results The disease control rate in the observation group was 90.57%(48/53)compared with 86.54%(45/52)in the control group,with no significant difference(P>0.05).After treatment,the lowest PLT value of the two groups was higher than that before treatment,and the tumor markers were lower than that before treatment,and the lowest PLT value of the observation group was higher than that of the control group,and there was no statistically significant difference between the tumor markers and the control group after treatment(P>0.05).It took(3.78±1.12)d for platelet recovery to 75×10^(9)/L or above,and(5.74±1.32)d for platelet recovery to 100×10^(9)/L or above,which were significantly shorter than(5.23±1.25)d and(8.97±1.46)d in the observation group,and the difference was statistically significant(P<0.05).There were no statistically significant differences in the incidence of side effects such as thrombocytopenia,decreased hemoglobin,neutropenia,decreased white blood cells,gastrointestinal reactions,liver function damage,peripheral nerve abnormalities,alopecia and fever between 2 groups(P>0.05).Conclusion rhTPO combined with paclitaxel and carboplatin chemotherapy in the treatment of advanced ovarian cancer can increase the number of platelets without increasing side effects,which is worthy of clinical application.